Clinical trial
R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma
NCT00450801 · University of Miami, Other · Completed
Key facts
| NCT number | NCT00450801 |
|---|---|
| Title | R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma |
| Official title | Phase II Study of Rituximab in Combination With Methotrexate, Doxorubicin, Cyclophosphamide, Leucovorin, Vincristine, Ifosfamide, Etoposide, Cytarabine and Mesna (MACLO/IVAM) in Patients With Previously Untreated Mantle Cell Lymphoma |
| Lead sponsor | University of Miami, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Rituximab, Cyclophosphamide, Cytarabine, Doxorubicin, Etoposide, Ifosfamide, Leucovorin, Methotrexate, Thalidomide, Vincristine and 4 more |
| Enrollment | 22 |
| Start date | Apr 1, 2004 |
| Primary completion | Jul 1, 2015 |
| Completion | Jul 1, 2015 |
| First posted | Mar 22, 2007 |
| Last update posted | Nov 10, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: